A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like ...

Ozempic was first approved to treat diabetes in Canada seven years ago. Now the largest study of its kind suggests it and ...

New drug approvals and a federal dementia care pilot program among the year's significant developments, according to the ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

Last year Roche, a Swiss pharmaceutical firm, published a review of the clinical trials on neurological drugs ... the first drugs against Alzheimer’s that seem to slow the progress of the ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Eli Lilly ( LLY 1.80%) and Novo Nordisk ( NVO 2.76%) are two of the most valuable healthcare stocks in the world, largely due ...

A study by Washington University School of Medicine and the VA St. Louis Health Care System has found that GLP-1 drugs can ...

STOCKHOLM, SE / ACCESSWIRE / January 21, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

And though drugs that have some effect on Alzheimer’s disease, dementia’s most common manifestation, have recently been assessed in America and Britain, not everyone is convinced.